Caplin Point acquires 10 approved ANDAs to strengthen US injectables, ophthalmic portfolio

Caplin Point Laboratories Ltd.

has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic drug manufacturer, strengthening its presence in regulated markets, particularly the US, the company announced in an exchange filing on Thursday, January 1.

The company said the acquisition was executed through its subsidiaries Caplin Steriles Ltd. (CSL) and Caplin One Labs Ltd. (COL). The acquired portfolio had an addressable market of $473.2 million for the 12-month period ended August 2025.

The company did not disclose the financial consideration for the transaction.

Caplin Point Chairman CC Paarthipan said, “The US market remains a key growth engine for the Company, and this acquisition meaningfully accelerates our strategy by expanding and strengthening our portfolio in the region."

"The acquired portfolio also includes select oncology injectables, which will be transferred to and commercialised from our new dedicated oncology facility in Kakkalur," he added, revealing the company's expansion plans "to key non-US markets, including Mexico, Canada, the European Union, and Brazil.”

Caplin Steriles, which focuses on sterile formulations, has filed 53 ANDAs in the US, with 49 approvals so far, including acquired products. It is also working on a pipeline of over 55 injectable and ophthalmic products planned for filing over the next four years.

Caplin One Labs, which operates the oncology unit at Kakkalur, has acquired five of the 10 ANDAs under the current transaction.

Caplin Point primarily serves emerging markets in Latin America and Africa, but has been steadily scaling its footprint in regulated markets through its sterile and oncology platforms.

The company reported an 18% year-on-year increase in net profit to ₹154.4 crore for the September quarter, compared to ₹130.8 crore a year earlier. Revenue grew 10.6% to ₹534 crore from ₹483 crore. EBITDA rose 15% to ₹189.2 crore, up from ₹164.7 crore last year, while operating margins improved to 35.4% from 34.1%.

Shares of Caplin Point Laboratories surged following the announcement reaching intraday highs of ₹1,871, but has since come down and were trading 0.6% lower at ₹1,827.1. The stock is down 27% for the last 12 months.